Continita

N/A

Report date: 2022/01/05 15:24:33
NME

Base Information

Drug NameContinita
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVascular endothelial growth factor receptor 2 inhibitorsHistone deacetylase 6 inhibitorsAXL receptor tyrosine kinase inhibitors
TargetsVascular endothelial growth factor receptor 2Histone deacetylase 6AXL receptor tyrosine kinase
Therapy Area/IndicationsStomach NeoplasmsColorectal NeoplasmsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesGuangzhou Yingsheng Bio Technology Co LtdBeijing Konruns Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGuangzhou Yingsheng Bio Technology Co LtdBeijing Konruns Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsStomach NeoplasmsColorectal NeoplasmsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A